About
Interested in Biotech, AI Infrastructure, Robotics, and Defense.
FO / Personal…
FO / Personal…
Activity
4K followers
-
Justin Chen Li, CFA reposted thisJustin Chen Li, CFA reposted this543 days. In 543 days we went from standing up a new company, Claros, to a $232.8M outcome. Claros is a perfect example of what the Red Cell Partners model and platform can achieve, in hardware no less. Congratulations to Daniel Kultran, the Claros team, and our fellow investors. Onward and upward!
-
Justin Chen Li, CFA reposted thisJustin Chen Li, CFA reposted thisThe partnerships that matter most are the ones that help turn great technology into real-world impact. That’s why I’m excited to see Red Cell Partners portfolio company Andesite and Booz Allen Hamilton working together. Cyber defenders are being asked to operate against threats moving at unprecedented speed and scale. Meeting that challenge will require more than simply adding AI to existing workflows — it will require pairing machine speed with human expertise, judgment, and accountability. Andesite is building the Human-AI SOC around that principle. Booz Allen brings deep operational experience and the ability to help bring advanced cyber capabilities into some of the most demanding environments in the world. This is exactly the kind of collaboration we need to accelerate the next generation of cyber defense. Congratulations to Brian Carbaugh, the Andesite team, Raynor Dahlquist, and the Booz Allen team. #Cybersecurity #AI #nationalsecurity-news https://lnkd.in/eC-kCFgQ
-
Justin Chen Li, CFA reposted thisJustin Chen Li, CFA reposted thisTrase has raised a $107 million seed round led by ARCH Venture Partners. Trase’s agentic operating system, Trase Origin, was built for elite, high-stakes organizations, designed to ensure data sovereignty, auditability, predictability, and governance across workflows. Trusted where failure is not an option, Trase has successfully deployed specialized AI agents inside Duke University Health System's Division of Cardiology. The early results speak for themselves: fax triage that is 7.1x faster, 1,395 hours returned to clinical staff each month, and $285K+ in annual staff capacity reinvested in patient care. CEO Grant Verstandig and President Baskar Sridharan share their rationale for bringing AI to mission-critical industries and why the hardest part isn't building the agents, but the infrastructure that makes them trustworthy: https://lnkd.in/eRPRHq9K #Trase #SeedRound #FundRaise #AIAgents #VentureStudio #ImpactThroughInnovation
-
Justin Chen Li, CFA reposted thisJustin Chen Li, CFA reposted thisMeet the team: Sharon Liang, Vice President of Regulatory and Quality Affairs👏 At Helio Genomics, Sharon Liang leads regulatory and quality affairs guiding the regulatory strategy behind HelioLiver and helping ensure the highest standards of quality, compliance, and patient safety. Drawing on nearly a decade of experience at the FDA, as well as leadership roles at GRAIL, Burning Rock, and Bristol Myers Squibb, Sharon helps bring innovative cancer detection technologies to patients while navigating the complex regulatory landscape. For Sharon, the mission is clear: “At Helio Genomics, we have an opportunity to make a meaningful impact by advancing early cancer detection. By maintaining the highest standards of quality and regulatory excellence, we help ensure innovative technologies can reach the patients who need them most.” We’re proud to have team members like Sharon helping advance our mission of detecting cancer earlier and improving patient outcomes. #MeetTheTeam #HelioGenomics #HelioLiver #EarlyCancerDetection #RegulatoryAffairs #Quality #PrecisionMedicine
-
Justin Chen Li, CFA reposted thisJustin Chen Li, CFA reposted thisThe fax machine is a relic. And yet, there are thousands of health systems that rely on an antiquated technology day in and day out for critical functions like prescription refills. Duke Health's Division of Cardiology receives thousands of them a month – each one manually sorted by a nurse or medical assistant who went to school for years to care for patients, not push paper. On a Monday morning in mid-April, we turned on Trase's fax routing agent for the first time. By the end of the day, it had processed 800+ faxes. In the weeks that followed, we delivered 7.1x faster triage, with 98.1% accuracy, and returned 1,395 hours to clinical staff every month to be allocated to higher order (i.e. patient-focused) cases. The fax problem sounds small – in the full scope of American healthcare, maybe it is – but it's where you prove your approach works before you bring it somewhere that matters more. Countless start ups focus either on administrative or clinical use cases, the reality is healthcare is about the intersection between the two. What we have built at Trase is the unbreakable foundation for America’s mission-critical industries. Trase Origin is an agentic operating system that helps manage agents like employees — with the same access controls, audit trail, and compliance requirements as any human staffer — purpose-built for the regulated environments where sovereignty, predictability, and accountability are non-negotiable. Today, Trase announced its $107M seed round, led by Bob Nelsen and ARCH Venture Partners. ARCH has spent nearly four decades backing companies that have reshaped healthcare; they understand that AI's biggest impact will be on the high-stakes American institutions that have been bogged down by inefficient systems for far too long. More of our thoughts on this incredible moment in our new blog: https://lnkd.in/eptNWX6j
-
Justin Chen Li, CFA shared thisI spent the day at Red Cell Partners HQ in D.C. with CEO Grant Verstandig. Red Cell is building a serious ecosystem of category-defining companies in some of the toughest industries: DEFCON AI just closed a $115M contract with USMC. Zephyr AI raised $111M from Eli Lilly and others and built one of the world’s largest multimodal clinicogenomics data sets for precision medicine. I’m particularly excited about Trase Systems, which sits at the orchestration layer of enterprise AI agents, solving the problem of high token costs and data governance (providing on-premises and air-gapped deployment that protect sensitive data), especially in highly regulated industries such as healthcare and defense. I’m excited to announce that I participated in Trase’s $107M oversubscribed seed round led by ARCH Venture Partners which was just announced on Axios today. Grant previously exited Rally Healthcare to United Health Group for $4B, and cofounded Epirus, which raised a $250M Series D last year to scale production of its High Power Microwave (HPM) drone defense technology. Sometimes, like Elon Musk and Palmer Luckey, you bet on the founder, and on that note, Grant doesn’t miss. https://lnkd.in/giWzaK3x
-
Justin Chen Li, CFA reposted thisJustin Chen Li, CFA reposted thisMost objects in orbit today are Starlink satellites. SpaceX has launched more than 12,000 Starlink satellites to date, of which 8,600 are active. SpaceX is only a few hundred satellites away from having launched as many satellites as the rest of the world combined, all time, despite having given the world a 61-year head start. As with launch, however, there is a wide gulf between SpaceX and the field. This material is solely for educational purposes and is not investment advice or an offer of investment advisory services. This material should not be used as the basis for an investment decision. a16z is an investor in SpaceX through its managed funds, and thus has a financial interest in the company’s performance and future prospects. In particular, a16z benefits if the company grows in value; and a16z funds will receive any customary dividend payments in connection with their status as a shareholder of the company. However, a16z is not being compensated by SpaceX for this material.
-
Justin Chen Li, CFA shared thisI had a blast co-hosting dinner with the Chainsmokers / Mantis Venture Capital in Bel Air for our Spark Family Offices community last week. Its been incredible watching Alex Pall and Drew go from global music icons to top decile VCs and early investors in Kalshi, Chainguard, Dandy, Underdog and other breakout companies. Fund 4, let’s go!! ⚡️🚀
-
Justin Chen Li, CFA reposted thisJustin Chen Li, CFA reposted thisIn-Q-Tel invested in Harbinger last week. IQT is the not-for-profit strategic investor for the U.S. national security community and America's allies. They fund technologies where performance is mandatory. They don't back companies built to fail. The platform they invested in is the same one delivering packages in Los Angeles. Same battery systems. Same drivetrain. Same clean-sheet chassis. Now configured for defense applications under Harbinger Praesidia. Fleet operators commit to platform partners for 10 years or more. The company vetting suppliers for national security just ran the same evaluation. IQT's answer last week was yes.
Justin Chen Li, CFA replied to a comment
3mo
Allyson Smart, SPHR amazing to hear that feedback
Justin Chen Li, CFA replied to a comment
3mo
Annette Walker very true words. Thank you for leading by example!
-
Justin Chen Li, CFA liked thisJustin Chen Li, CFA liked thisThe Red Cell Fund team is hiring!! Looking for a wonderful DC-based VP of IR to lead investor relations for our growing platform. Job description below: https://lnkd.in/g6Ff46Bn
-
Justin Chen Li, CFA liked thisI speak for our entire SoCal/OC community…we are thrilled to continue to support Renata Medical through the SC Master Fund. 👶🏼❤️🩹🫀🩻🩺👩🏽⚕️👨🏻⚕️🧑🏼⚕️📈🏥 Richard Gochnauer Justin Chen Li, CFA Chris Seib CEO Leadership Alliance Orange County (CLAOC)Justin Chen Li, CFA liked thisWe're proud to announce we have just closed a $25M Series D financing round — led by ARCHIMED, with participation from our existing investors. This capital lets us do more of what we set out to do: get the Minima Stent System into more hands, in more countries, faster — and keep building the pipeline of pediatric-specific technology behind it. Since our 2024 commercial launch, adoption of Minima has outpaced our own expectations. Congenital heart programs are seeing what happens when a device is actually built for a child's anatomy — not adapted from one built for an adult. A huge thank you to ARCHIMED, led by André-Michel Ballester, for recognizing that gap and backing our team to close it — and to our existing investors for their continued support. Read the full press release here: https://lnkd.in/giwcZ8fYRenata Medical Closes $25M Series D Financing Led by Global Healthcare Investment Firm ARCHIMED to Accelerate Commercialization and Development of Pediatric Cardiovascular TechnologiesRenata Medical Closes $25M Series D Financing Led by Global Healthcare Investment Firm ARCHIMED to Accelerate Commercialization and Development of Pediatric Cardiovascular Technologies
-
Justin Chen Li, CFA liked thisJustin Chen Li, CFA liked this543 days. In 543 days we went from standing up a new company, Claros, to a $232.8M outcome. Claros is a perfect example of what the Red Cell Partners model and platform can achieve, in hardware no less. Congratulations to Daniel Kultran, the Claros team, and our fellow investors. Onward and upward!
-
Justin Chen Li, CFA liked thisJustin Chen Li, CFA liked thisThe partnerships that matter most are the ones that help turn great technology into real-world impact. That’s why I’m excited to see Red Cell Partners portfolio company Andesite and Booz Allen Hamilton working together. Cyber defenders are being asked to operate against threats moving at unprecedented speed and scale. Meeting that challenge will require more than simply adding AI to existing workflows — it will require pairing machine speed with human expertise, judgment, and accountability. Andesite is building the Human-AI SOC around that principle. Booz Allen brings deep operational experience and the ability to help bring advanced cyber capabilities into some of the most demanding environments in the world. This is exactly the kind of collaboration we need to accelerate the next generation of cyber defense. Congratulations to Brian Carbaugh, the Andesite team, Raynor Dahlquist, and the Booz Allen team. #Cybersecurity #AI #nationalsecurity-news https://lnkd.in/eC-kCFgQ
-
Justin Chen Li, CFA liked thisJustin Chen Li, CFA liked thisLet’s go!! Today may mark the beginning of a new era in cancer treatment. Moderna and Merck have reported landmark results from a Phase 3 trial of an individualized mRNA cancer therapy. The study enrolled 1,137 patients with high-risk melanoma following surgery. Intismeran autogene plus KEYTRUDA met both its primary endpoint of recurrence-free survival and a key secondary endpoint measuring whether the cancer spread elsewhere in the body, with no new safety concerns reported. Each treatment is custom-built from the mutations in a patient’s own tumor—training the immune system to recognize and attack that individual’s cancer. These findings build on an earlier, smaller Phase 2 study showing a 49% reduction in recurrence or death and a 59% reduction in distant metastasis or death at five years. This is a major milestone for patients, personalized medicine, and the promise of mRNA far beyond infectious disease. Congratulations to the patients, researchers, and teams at Moderna and Merck who made it possible.Moderna Shares More Than Double on Success of mRNA Cancer VaccineModerna Shares More Than Double on Success of mRNA Cancer Vaccine
-
Justin Chen Li, CFA liked thisJustin Chen Li, CFA liked thisPhysicians don't go into medicine to parse through mountains of paperwork. So we built a secure system that handles it at least 7x faster – giving them and their care teams more free time to spend with patients. In a recent conversation, Duke University Health System's Manesh Patel, MD, MD and our President Baskar Sridharan broke down how we saved Duke's clinical staff nearly 1,400 hours of admin work with a single fax routing agent, and how Trase is working towards eliminating administrative burden in healthcare for good. Learn more about our work with Duke: https://lnkd.in/epAmtep8 #AIInfrastructure #AIAgent #HealthcareAI #DukeHealth
-
Justin Chen Li, CFA liked thisJustin Chen Li, CFA liked thisCan an 8 mm liver tumor be detected before routine surveillance finds it? This real-world case from the CLiMB Trial illustrates the importance of detecting hepatocellular carcinoma (HCC) while lesions are still small. 📍 Clinical Summary Routine HCC surveillance • High-risk patient with cirrhosis • Standard abdominal ultrasound performed • No lesion detected 🩸 HelioLiver® • Blood test returned positive • Follow-up MRI identified an 8 mm hepatocellular carcinoma (HCC) • Stage T1, while still within the curative treatment window 📊 Key CLiMB Trial Finding This case illustrates one of the key findings from the CLiMB Trial: • Ultrasound detected 0% of HCC lesions smaller than 2 cm during a single surveillance visit. • HelioLiver® detected 28.6% of HCC lesions smaller than 2 cm, including tumors as small as 8 mm. For patients at high risk of liver cancer, detecting HCC while lesions are still small may provide an opportunity for earlier intervention and potentially curative treatment. Because in liver cancer, every millimeter matters. 📖 Reference CLiMB Trial – A multi-analyte cfDNA-based blood test for early detection of hepatocellular carcinoma. Journal of Hepatology (2026). https://lnkd.in/gXsnX2wU #LiverCancer #HCC #EarlyDetection #PrecisionMedicine #LiquidBiopsy #CLiMBTrial #Hepatology #HelioLiver This case is shared for educational purposes. Individual patient outcomes may vary, and clinical decisions should always be based on the complete clinical picture.
Experience & Education
Licenses & Certifications
Honors & Awards
-
Chartered Financial Analyst
CFA Institute
Successfully completed all 3 levels of the CFA on first attempt. Received CFA designation on Aug 2017.
http://basno.com/y8h8gkey -
Member of NSCS
National Society of Collegiate Scholars
-
Dean's Honor List
University of Colorado at Boulder
Dean's Honor List 5 Semesters at University of Colorado at Boulder
Other similar profiles
Explore more posts
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top content